Floatz logo

ABATACEPT RECOMBINANT

MDS Associated With Isolated Del (5q)

Boston Children's Hospitalprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the MDS Associated With Isolated Del (5q) cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Mayo Clinic
Phase 2BB
METHOTREXATE
National Cancer Institute (NCI)
Phase 3BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 3BB
TACROLIMUS
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB

View all 15 →

Same molecule, other indications

ABATACEPT RECOMBINANT is also rated in:

Primary Biliary CholangitisDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →